Details for New Drug Application (NDA): 208075
✉ Email this page to a colleague
NDA 208075 describes CEFTAROLINE FOSAMIL, which is a drug marketed by Apotex and is included in one NDA. Additional details are available on the CEFTAROLINE FOSAMIL profile page.
The generic ingredient in CEFTAROLINE FOSAMIL is ceftaroline fosamil. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ceftaroline fosamil profile page.
The generic ingredient in CEFTAROLINE FOSAMIL is ceftaroline fosamil. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ceftaroline fosamil profile page.
Summary for 208075
| Tradename: | CEFTAROLINE FOSAMIL |
| Applicant: | Apotex |
| Ingredient: | ceftaroline fosamil |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | POWDER;INTRAVENOUS | Strength | 400MG/VIAL | ||||
| Approval Date: | Sep 21, 2021 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | POWDER;INTRAVENOUS | Strength | 600MG/VIAL | ||||
| Approval Date: | Sep 21, 2021 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
